Phase II Study of Bevacizumab and Pemetrexed for Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

OBJECTIVE: To evaluate the efficacy and safety of combination bevacizumab/pemetrexed for the treatment of recurrent epithelial ovarian cancer (EOC). METHODS: Platinum-sensitive or -resistant patients with recurrent or persistent EOC were eligible if they had received up to 2 prior chemotherapy regim...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Hagemann, Andrea R., Novetsky, Akiva P., Zighelboim, Israel, Gao, Feng, Massad, L. Stewart, Thaker, Premal H., Powell, Matthew A., Mutch, David G., Wright, Jason D.
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3939037/
https://ncbi.nlm.nih.gov/pubmed/24096113
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2013.09.032
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares